Category Archives: Myocardial Infarction

Pediatrician Tomisaku Kawasaki, famed fordiscovering the inflammatory syndrome of an unknown cause in young children later named after him,died June 5 of old age in a Tokyo hospital. He was 95. Continue reading →

Heart attacks happen when an artery supplying your heart with blood and oxygen becomes blocked, usually by a blood clot. The most common underlying cause of blood clots is coronary heart disease (CHD), a process whereby coronary arteries (the major blood vessels that supply the heart with blood) become clogged with deposits of cholesterol. These deposits are called plaques Continue reading →

Hemostatic is the stopping of bleeding from a body, blood flow from any blood vessel agents or a body part. Continue reading →

Acute myocardial infarction (AMI) is more likely among patients on hemeodialysis than in those on peritoneal dialysis (PD), a new study found. Among 86,215 patients initiating maintenance dialysis during 1998 to 2010 in Taiwans National Health Insurance Research Database, investigators identified 5513 pairs of HD and PD patients matched by age, sex, year of dialysis initiation, and 20 relevant comorbidities such as diabetes, hypertension, heart failure, and coronary artery disease Continue reading →

Roughly one third of patients hospitalized with COVID-19 have some degree of myocardial injury and these patients are at an increased risk of death when compared with patients who lack elevations in cardiac troponin levels, according to a new analysis. Continue reading →

The risk for stroke associated with the use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDS) varies between different monotherapies, according to study results presented at the European League Against Rheumatism (EULAR) 2020 E-Congress, held online from June 3 to 6, 2020. Using data from 6 electronic health records databases across Germany, the United States, and the United Kingdom, investigators aimed to assess the effects of various csDMARDS on the risk for cardiovascular and cerebrovascular events in patients with rheumatoid arthritis (RA). Continue reading →

A history of myocardial infarction (MI) was found to be associated with enhanced risk for cardiovascular (CV) death, particularly sudden death, according to study results published in JACC: Heart Failure. This was a pooled analysis of individual patient-level data from 3 multicenter, randomized, double-blind, placebo-controlled trials in which pharmacotherapy for HFpEF was examined: Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (ClinicalTrials.gov identifierNCT00634712; n=3023), Irbesartan in Heart Failure With Preserved Systolic Function (ClinicalTrials.gov identifier: NCT00095238; n=4128) and Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (ClinicalTrials.gov identifier: NCT00094302; n=1765)in a total of 8916 patients with symptomatic HFpEF Continue reading →

Background:Visfatin is an adipokine that related with the inflammation in atherosclerosis and the destabilization of atherosclerotic plaque. The aim of this study was to observe the relationship between visfatin and major adverse cardiovascular events (MACEs) in acute myocardial infarction (AMI) patients Continue reading →

Coronary heart disease (CHD) is the most common cause of heart disease and serious cause of early death in developed countries around the world. Stress hyper-glycaemia has a bad prognostic implication in hospital outcomes in acute ST elevated myocardial infarction patients. Continue reading →

Background: Left ventricular ejection fraction (EF) recovery is associated with better long-term outcomes after myocardial infarction (MI). However, the association between long-term outcomes and EF recovery among young MI patients has not been investigated Continue reading →